Go-To-Market (GTM) planning is becoming increasingly challenging. Investors expect sharper plans. AI and China’s rapid innovation open new paths for BD&L and R&D, while intensifying global competition. Political headwinds make ex-US success more important, while breakthrough modalities (from obesity drugs to stem cell and rare-disease therapies) demand more innovative, sustainable commercialisation models.
More questions, fewer hands, and less time.
Winning now requires smarter and truly glocal GTM planning anchored in local market nuance. However, many consultancies still struggle to bring in enough market understanding to integrate CN-US-EU perspectives, reduce budget-padding for overheads and training junior staff, or work with the agility that biopharma requires in this new environment.
This is why I founded Vivara: to help bring more treatments to patients with GTM plans built for today’s reality. I offer the extremely rare combination of deep China and Western market expertise, shaped by hands-on GTM work across the US, EU5 and China, and 15+ years supporting both first-launch biotechs and large pharma. With Vivara, you get a partner who truly understands local market nuances and global perspectives, so you can prioritise opportunities, de-risk decisions, and execute with confidence.
Veritux independent consultants are available where you need them – in all major markets and every global region.
